PIM Kinases in Multiple Myeloma

PIM Kinases in Multiple Myeloma

Multiple myeloma (MM) remains an incurable disease and novel therapeutic agents/approaches are urgently needed. The PIM (Proviral insertion in murine malignancies) serine/threonine kinases have 3 isoforms: PIM1, PIM2, and PIM3. PIM kinases are engaged with an expansive scope of biological activities...

Full description

Bibliographic Details
Main Authors:	Jian Wu, Emily Chu, Yubin Kang
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Cancers
Subjects:	PIM kinase multiple myeloma resistance inhibitor PI3K/Akt/mTOR
Online Access:	https://www.mdpi.com/2072-6694/13/17/4304

Similar Items

Novel Library of Selenocompounds as Kinase Modulators
by: Carmen Sanmartín, et al.
Published: (2011-07-01)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
by: Gillian Moore, et al.
Published: (2021-04-01)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
by: Teresa Paíno, et al.
Published: (2020-09-01)

PIWI-Interacting RNA-004800 Is Regulated by S1P Receptor Signaling Pathway to Keep Myeloma Cell Survival
by: Huanxin Ma, et al.
Published: (2020-04-01)

Pathway-Directed Therapy in Multiple Myeloma
by: Lukas John, et al.
Published: (2021-04-01)

mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01)

Autophagy as a Vital Therapy Target for Renal Cell Carcinoma
by: Ying-hua He, et al.
Published: (2021-02-01)

PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
by: Aziz Ur Rehman Aziz, et al.
Published: (2018-02-01)

Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
by: Kasun Wanigasooriya, et al.
Published: (2020-05-01)

Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01)

Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
by: Paolo Uva, et al.
Published: (2021-06-01)

Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors
by: Shuang Cao, et al.
Published: (2016-07-01)

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
by: Qin Xia, et al.
Published: (2020-10-01)

“Immune TOR-opathies,” a Novel Disease Entity in Clinical Immunology
by: Sophie Jung, et al.
Published: (2018-05-01)

Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
by: Agata Majchrzak, et al.
Published: (2014-09-01)

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
by: Nazanin Momeni Roudsari, et al.
Published: (2021-08-01)

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas
by: Joanna M. Janus, et al.
Published: (2017-07-01)

The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
by: Charles N. Landen, et al.
Published: (2013-04-01)

Regulation of Autophagy by Kinases
by: Savitha Sridharan, et al.
Published: (2011-06-01)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
by: Huayi Li, et al.
Published: (2021-07-01)

Synthèse d’inhibiteurs pyridopyrimidiniques de la voie PI3K/Akt/mTOR et mise au point de tests enzymatiques dans l’évaluation de leurs activités inhibitrices
by: Saurat, Thibault
Published: (2012)

The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor
by: Jie Pan, et al.
Published: (2020-04-01)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging Therapeutic Opportunities
by: Paul A Hubbard, et al.
Published: (2014-12-01)

Computational Modelling of the Metabolic States Regulated by the Kinase Akt
by: Ettore eMosca, et al.
Published: (2012-11-01)

Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases
by: Antonietta Fazio, et al.
Published: (2020-07-01)

Essai du traitement pré-clinique du carcinome hépatocellulaire sur la cirrhose dans le modèle de rat
by: Zeybek, Ayça
Published: (2016)

The Role of mTOR Signaling as a Therapeutic Target in Cancer
by: Nadezhda V. Popova, et al.
Published: (2021-02-01)

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
by: Ina Nepstad, et al.
Published: (2020-04-01)

Cyclophosphamide Inhibits PI3K/AKT/mTOR Signaling Pathway in Mice Kidneys
by: Gulsah Albayrak, et al.
Published: (2018-12-01)

AKTivation of the PI3K/AKT/mTOR signaling pathway by KSHV
by: Aadra P Bhatt, et al.
Published: (2013-01-01)

Does the PI3K pathway promote or antagonise regulatory T cell development and function?
by: Dalya R Soond, et al.
Published: (2012-08-01)

Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition
by: Sun Z, et al.
Published: (2018-08-01)

The Role of PI3K in Met Driven Cancer: A Recap
by: Alexia Hervieu, et al.
Published: (2018-10-01)

Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress
by: Yi Duan, et al.
Published: (2020-10-01)

New Approaches to Target T-ALL.
by: Giovanni eRoti, et al.
Published: (2014-07-01)

Polydatin regulates proliferation, apoptosis and autophagy in multiple myeloma cells through mTOR/p70s6k pathway
by: Yang B, et al.
Published: (2017-02-01)

Insulin receptor substrate 1 is a substrate of the Pim protein kinases
by: Song, Jin H., et al.
Published: (2016)

Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer
by: Hong Li, et al.
Published: (2021-08-01)

Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3′-kinase/protein kinase B/mammalian target of rapamycin pathway
by: Liu, J., et al.
Published: (2022)

Metformin - its anti-cancer effects in hematologic malignancies
by: Monika Podhorecka
Published: (2021-02-01)